United Kingdom Hepatitis Delta Virus (HDV) Infection Market Insight
The United Kingdom Hepatitis Delta Virus (HDV) Infection Market is growing at an 6.31% CAGR, driven by rising awareness of severe viral hepatitis, improved screening, NHS elimination programs, antiviral therapy advancements, combination treatments, HBV coinfection management, and increasing hospital diagnosis and specialist liver care services
United Kingdom Hepatitis Delta Virus (HDV) Infection Market Insights Forecasts to 2035
- The United Kingdom Hepatitis Delta Virus (HDV) Infection Market Size Was Estimated at USD 2.05 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 6.31% from 2025 to 2035
- The United Kingdom Hepatitis Delta Virus (HDV) Infection Market Size is Expected to Reach USD 3.78 Million by 2035
Notable Insights for United Kingdom Hepatitis Delta Virus (HDV) Infection Market
- By drug class, nucleos(t)ide analogues dominate the market, accounting for approximately 70–75% share, due to their role in suppressing HBV co-infection, which is essential in HDV management.
- By therapy type, long-term antiviral therapy leads the segment with approximately 60–65% share, driven by chronic HBV/HDV coinfection treatment requirements.
- HDV remains a rare but high-severity infection in the UK, primarily affecting patients already living with chronic Hepatitis B, particularly in migrant and high-risk populations.
- Around 65–75% of diagnosed patients receive long-term antiviral management, while a smaller subset undergoes interferon-based or investigational combination therapies
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Hepatitis Delta Virus (HDV) Infection Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Hepatitis Delta Virus (HDV) Infection Market
- Gilead Sciences
- GlaxoSmithKline
- Roche
- Johnson & Johnson
- Bristol Myers Squibb
- AbbVie
- Merck & Co.
- Teva Pharmaceutical Industries
- Others
Recent Developments:
- In July 2025, IARC (WHO) classified hepatitis D virus as carcinogenic to humans, reinforcing its role in liver cancer development and increasing urgency for early diagnosis, screening, and treatment access.
- In August 2023, bulevirtide (Hepcludex) received full UK marketing authorization for chronic hepatitis D, expanding treatment access and strengthening HDV management within specialist liver care pathways across NHS settings.
Market Segmentation:
United Kingdom Hepatitis Delta Virus (HDV) Infection Market, By Drug Class
- Nucleos(t)ide Analogues (Tenofovir, Entecavir)
- Interferons (Pegylated Interferon)
- Combination Therapies
- Others
United Kingdom Hepatitis Delta Virus (HDV) Infection Market, By Route of Administration
- Oral
- Injectable
United Kingdom Hepatitis Delta Virus (HDV) Infection Market, By End User
- Hospitals & Clinics
- Home Care Settings
- Specialty Liver Centers
United Kingdom Hepatitis Delta Virus (HDV) Infection Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Channels
Expert Views:
Experts indicate that the UK Hepatitis Delta Virus (HDV) Infection Market will grow gradually due to improved screening of HBV patients, rising awareness of HDV severity, and NHS-driven liver disease elimination strategies. While treatment options remain limited, interferon-based therapy and emerging antiviral combinations continue to dominate clinical practice. Future growth is expected to be shaped by novel antiviral development and functional cure research targeting HBV/HDV coinfection through 2035.